Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Mar 29 2011 Cyclacel announces abstracts selected for presentation at American Association for Cancer Research Annual Meeting Mar 23 2011 Cyclacel Pharmaceuticals reports fourth quarter and full year 2010 financial results Mar 07 2011 Cyclacel to announce year end & fourth quarter 2010 financial results and presentation at upcoming conference Feb 17 2011 Data Published in the Proceedings of the National Academy of Sciences highlight Feb 01 2011 Cyclacel Pharmaceuticals to present at the 13th Annual BIO CEO & Investor Conference Jan 11 2011 Cyclacel begins pivotal Phase 3 “SEAMLESS” trial of sapacitabine as front-line treatment for AML under a SPA Jan 06 2011 Cyclacel reviews 2010 achievements and key clinical development objectives for 2011 Dec 21 2010 Cyclacel announces topline results from APPRAISE Phase 2b study of seliciclib Dec 05 2010 Cyclacel’s second-generation cyclin-dependent kinase inhibitor CYC065 demonstrates activity in multiple myeloma Dec 04 2010 Cyclacel reports Phase 2 survival data with sapacitabine in myelodysplastic syndromes at 2010 ASH annual meeting Dec 04 2010 Cyclacel reports Phase 2 survival data with sapacitabine in myelodysplastic syndromes at 2010 ASH annual meeting Nov 19 2010 Cyclacel Pharmaceuticals to present sapacitabine Phase 2 MDS data at the upcoming American Society of Hematology meeting Nov 12 2010 Cyclacel to present at upcoming conferences Nov 11 2010 Cyclacel Pharmaceuticals reports third quarter 2010 financial results Nov 10 2010 Publications highlight novel combinations of sapacitabine with targeted agents for the treatment of cancer Nov 04 2010 Cyclacel pharmaceuticals to announce release of third quarter 2010 financial results Oct 07 2010 Cyclacel completes previously announced private placement Oct 06 2010 Cyclacel announces adjournment of special preferred stockholders meeting Oct 06 2010 Cyclacel announces adjournment of special preferred stockholders meeting Oct 05 2010 Cyclacel announces private placement financing for up to $22.1 million Sep 29 2010 Cyclacel to present at BIO Investor Forum Sep 13 2010 Cyclacel reaches agreement with FDA on a Special Protocol Assessment for pivotal Phase 3 trial of sapacitabine in AML Sep 08 2010 Cyclacel to present at annual Rodman & Renshaw healthcare conference Aug 13 2010 Cyclacel Pharmaceuticals’ 6% convertible exchangeable preferred stockholders request special meeting to elect directors Aug 05 2010 Cyclacel Pharmaceuticals reports second quarter 2010 financial results Pagination First page « first Previous page ‹ previous … Page 10 Page 11 Page 12 Page 13 Current page 14 Page 15 Page 16 Page 17 Page 18 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Mar 29 2011 Cyclacel announces abstracts selected for presentation at American Association for Cancer Research Annual Meeting Mar 23 2011 Cyclacel Pharmaceuticals reports fourth quarter and full year 2010 financial results Mar 07 2011 Cyclacel to announce year end & fourth quarter 2010 financial results and presentation at upcoming conference Feb 17 2011 Data Published in the Proceedings of the National Academy of Sciences highlight Feb 01 2011 Cyclacel Pharmaceuticals to present at the 13th Annual BIO CEO & Investor Conference Jan 11 2011 Cyclacel begins pivotal Phase 3 “SEAMLESS” trial of sapacitabine as front-line treatment for AML under a SPA Jan 06 2011 Cyclacel reviews 2010 achievements and key clinical development objectives for 2011 Dec 21 2010 Cyclacel announces topline results from APPRAISE Phase 2b study of seliciclib Dec 05 2010 Cyclacel’s second-generation cyclin-dependent kinase inhibitor CYC065 demonstrates activity in multiple myeloma Dec 04 2010 Cyclacel reports Phase 2 survival data with sapacitabine in myelodysplastic syndromes at 2010 ASH annual meeting Dec 04 2010 Cyclacel reports Phase 2 survival data with sapacitabine in myelodysplastic syndromes at 2010 ASH annual meeting Nov 19 2010 Cyclacel Pharmaceuticals to present sapacitabine Phase 2 MDS data at the upcoming American Society of Hematology meeting Nov 12 2010 Cyclacel to present at upcoming conferences Nov 11 2010 Cyclacel Pharmaceuticals reports third quarter 2010 financial results Nov 10 2010 Publications highlight novel combinations of sapacitabine with targeted agents for the treatment of cancer Nov 04 2010 Cyclacel pharmaceuticals to announce release of third quarter 2010 financial results Oct 07 2010 Cyclacel completes previously announced private placement Oct 06 2010 Cyclacel announces adjournment of special preferred stockholders meeting Oct 06 2010 Cyclacel announces adjournment of special preferred stockholders meeting Oct 05 2010 Cyclacel announces private placement financing for up to $22.1 million Sep 29 2010 Cyclacel to present at BIO Investor Forum Sep 13 2010 Cyclacel reaches agreement with FDA on a Special Protocol Assessment for pivotal Phase 3 trial of sapacitabine in AML Sep 08 2010 Cyclacel to present at annual Rodman & Renshaw healthcare conference Aug 13 2010 Cyclacel Pharmaceuticals’ 6% convertible exchangeable preferred stockholders request special meeting to elect directors Aug 05 2010 Cyclacel Pharmaceuticals reports second quarter 2010 financial results Pagination First page « first Previous page ‹ previous … Page 10 Page 11 Page 12 Page 13 Current page 14 Page 15 Page 16 Page 17 Page 18 … Next page next › Last page last »
Mar 29 2011 Cyclacel announces abstracts selected for presentation at American Association for Cancer Research Annual Meeting
Mar 07 2011 Cyclacel to announce year end & fourth quarter 2010 financial results and presentation at upcoming conference
Jan 11 2011 Cyclacel begins pivotal Phase 3 “SEAMLESS” trial of sapacitabine as front-line treatment for AML under a SPA
Dec 05 2010 Cyclacel’s second-generation cyclin-dependent kinase inhibitor CYC065 demonstrates activity in multiple myeloma
Dec 04 2010 Cyclacel reports Phase 2 survival data with sapacitabine in myelodysplastic syndromes at 2010 ASH annual meeting
Dec 04 2010 Cyclacel reports Phase 2 survival data with sapacitabine in myelodysplastic syndromes at 2010 ASH annual meeting
Nov 19 2010 Cyclacel Pharmaceuticals to present sapacitabine Phase 2 MDS data at the upcoming American Society of Hematology meeting
Nov 10 2010 Publications highlight novel combinations of sapacitabine with targeted agents for the treatment of cancer
Sep 13 2010 Cyclacel reaches agreement with FDA on a Special Protocol Assessment for pivotal Phase 3 trial of sapacitabine in AML
Aug 13 2010 Cyclacel Pharmaceuticals’ 6% convertible exchangeable preferred stockholders request special meeting to elect directors
